ReviewBritish journal of clinical pharmacology2013
New treatments for autosomal dominant polycystic kidney disease.
Review in British journal of clinical pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 46 citations in OpenAlex.
- High water vs. ad libitum water intake for autosomal dominant polycystic kidney disease: a randomized controlled feasibility trial.QJM : monthly journal of the Association of Physicians · 2020Trial
- Safety and tolerability of autologous bone marrow mesenchymal stromal cells in ADPKD patients.Stem cell research & therapy · 2017Trial
- Pharmacological Effects of Panduratin A on Renal Cyst Development in In Vitro and In Vivo Models of Polycystic Kidney Disease.International journal of molecular sciences · 2022Article
- Recent Discoveries in Epigenetic Modifications of Polycystic Kidney Disease.International journal of molecular sciences · 2021Review
- A high-throughput screening platform for Polycystic Kidney Disease (PKD) drug repurposing utilizing murine and human ADPKD cells.Scientific reports · 2020Article
- Predictors of Hyperuricemia after Kidney Transplantation: Association with Graft Function.Medicina (Kaunas, Lithuania) · 2020Article
- The Role of Endothelin and Endothelin Antagonists in Chronic Kidney Disease.Kidney diseases (Basel, Switzerland) · 2020Review
- Inhibition of HDAC6 activity in kidney diseases: a new perspective.Molecular medicine (Cambridge, Mass.) · 2018Review
- Is the light at the end of the tunnel nigh? A review of ADPKD focusing on the burden of disease and tolvaptan as a new treatment.International journal of nephrology and renovascular disease · 2018Review
- Polycystin and calcium signaling in cell death and survival.Cell calcium · 2018Review
- Histone deacetylase 6 inhibition reduces cysts by decreasing cAMP and CaThe Journal of biological chemistry · 2017Article
- Urinary proteomics using capillary electrophoresis coupled to mass spectrometry for diagnosis and prognosis in kidney diseases.Current opinion in nephrology and hypertension · 2016Review
- Relationship of urinary endothelin-1 with estimated glomerular filtration rate in autosomal dominant polycystic kidney disease: a pilot cross-sectional analysis.BMC nephrology · 2016Article
- Autosomal dominant polycystic kidney disease: recent advances in clinical management.F1000Research · 2016Review
- Nephrology research--the past, present and future.Nature reviews. Nephrology · 2015Review
- A polycystin-centric view of cyst formation and disease: the polycystins revisited.Kidney international · 2015Review
- Glycogen synthase kinase-3β promotes cyst expansion in polycystic kidney disease.Kidney international · 2015Article
- Polycystic kidney disease and cancer after renal transplantation.Journal of the American Society of Nephrology : JASN · 2014Article
- How simple are 'simple renal cysts'?Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2014Review
- Role of extracellular ATP and P2 receptor signaling in regulating renal cyst growth and interstitial inflammation in polycystic kidney disease.Frontiers in physiology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease and results from mutations in PKD1 or PKD2. Cyst initiation and expansion arise from a combination of abnormal cell proliferation, fluid secretion and extracellular matrix defects and results in kidney enlargement and interstitial fibrosis. Since its first description over 200 years ago, ADPKD has been considered an untreatable condition and its management is limited to blood pressure reduction and symptomatic treatment of disease complications. Results of the recently reported TEMPO 3/4 trial thus represent a paradigm shift in demonstrating for the first time that cystic disease and loss of renal function can be slowed in humans. In this paper, we review the major therapeutic strategies currently being explored in ADPKD including a range of novel approaches in preclinical models. It is anticipated that the clinical management of ADPKD will undergo a revolution in the next decade with the translation of new treatments into routine clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.